Research shows Radical Prostatectomy Might Result in Better Survival than External Beam Radiation Therapy for Some Patients Presenting with Metastatic Prostate Cancer

Categories: Summer/Fall 2021


Danube Bridge
Research continues to examine various methods to provide a bridge to more personalized care for metastatic prostate cancer patients.

Recent study results by Lara Stolzenbach and associates published in the International Journal of Urology shows that radical prostatectomy might result in better survival rates than external beam radiation therapy in some patients with newly diagnosed metastatic prostate cancer.

Records of 4280 newly diagnosed metastatic prostate cancer patients who had been treated with radical prostatectomy or external beam radiation were analyzed for prostate cancer-specific mortality. The 5-year prostate cancer-specific death rate was 47% in those treated with radical prostatectomy versus 53% in those treated with radiation therapy. Patients were matched for various risk factors to exclude any bias in one treatment over the other (i.e., age, PSA, Gleason grade group), the prostate cancer death rate was approximately 21% lower in those treated with prostatectomy.

They conclude that, in metastatic prostate cancer, radical prostatectomy results in lower cancer-specific mortality relative to external beam radiation therapy. As a result, radical prostatectomy should be considered as a treatment option in selected metastatic prostate cancer patients. However, further validation will be provided by ongoing clinical trials.

©Dan Oldfield




Subscribe to Quest

"*" indicates required fields


This email address is only for subscribing or unsubscribing to or from Quest. Dr. Catalona cannot respond to questions concerning your Personal Health Information (PHI) that could identify you as an individual. This is a "cyber-security measure" for your protection that will help prevent anyone from legally or illegally accessing your personal health information.

Delivery Method (How do you want to receive your Quest publication?)*